BTIG tells investors in a research note that Gilead’s (GILD) proposed acquisition of CymaBay (CBAY) “makes perfect sense,” as the firm sees seladelpar emerging as the preferred peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis and isn’t aware of any other PBC programs in Gilead’s pipeline. The firm made no change to its Buy rating or $26 price target on CymaBay shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- M & A News: Gilead (NASDAQ:GILD) Snaps Up CymaBay (NASDAQ:CBAY) for $32.50 Per Share
- CymaBay Therapeutics’ Strategic Merger with Gilead Sciences
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay price target raised to $26 from $22 at Oppenheimer
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes
